Business Wire

IDEMIA’s MorphoWaveTM Technology Demonstrates Full Interoperability and Surpasses All Other Contactless Devices in NIST’s Latest Contactless-to-Contact Fingerprint Capture Ranking

22.6.2020 11:00:00 EEST | Business Wire | Press release

Share

IDEMIA today announced that its MorphoWave TM contactless fingerprint technology outperformed all other devices in the National Institute of Standards and Technology (NIST)’s latest Accuracy and Interoperability Test on all criteria involved.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200622005215/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo Business Wire)

The primary reason for carrying out the “ Interoperability Assessment 2019: Contactless-to-Contact Fingerprint Capture ” study was to test how well touchless systems work with legacy databases. NIST tested six sold contactless fingerprint scanning technologies by comparing how they fared with conventional touch-based fingerprint devices. The results show that contactless devices that scanned multiple fingers consistently achieved better accuracy than single finger scanning and made less “false positive” errors that incorrectly matched a person’s print with someone else’s.

MorphoWave TM is a stand-out IDEMIA-developed technology that scans and checks four fingerprints in under a second by just waiving your hand within the reader. Shown as Dev03 in the report, MorphoWave TM consistently performs better than other contactless devices in terms of matching rate, image capture sample rate, areas of overlap between probe and exemplar fingerprints, finger ridges and minutiae similarity. Further testing was conducted with both contact and contactless probes matched to the MorphoWave TM exemplar contactless fingerprints.

This testing confirms MorphoWave TM, which already underpins the currently sold MorphoWave TM Compact, works well with legacy touch fingerprint scanners and other contactless solutions alike. It also highlights that this technology enables extremely efficient contactless fingerprint capture and matching against existing contact-based fingerprint databases. This latter feature is very beneficial for some government programs, border checks and minimizing passenger lines whenever user fingerprints are already held in a database. So MorphoWave TM gives passengers a smoother and more hygienic user experience.

IDEMIA CTO Jean-Christophe Fondeur said: “The recent COVID19 pandemic has ushered in growing demand for contactless and hygienic solutions. We are delighted to see contactless fingerprint capture that we pioneered is on the cusp of matching contact-based accuracy, and of course that our MorphoWave TM technology has emerged from this NIST interoperability test as the best in the industry. Given its outstanding capacity as borne out by this NIST test, our MorphoWave TM Compact is a game changer and will seamlessly raise hygiene standards in a vast array of environments including corporate offices, stores, airports, theme parks and leisure and entertainment venues.”

About NIST :

Founded in 1901, NIST is a non-regulatory federal agency within the U.S. Department of Commerce. NIST's mission is to promote U.S. innovation and industrial competitiveness by advancing measurement science, standards, and technology in ways that enhance economic security and improve our quality of life.

From smart electric power grid and electronic health records to atomic clocks, advanced nanomaterials and computer chips, innumerable products and services rely in some way on technology, measurement, and standards provided by the National Institute of Standards and Technology.

Link to Interoperability Assessment 2019: Contactless-to-Contact Fingerprint Capture study: https://nvlpubs.nist.gov/nistpubs/ir/2020/NIST.IR.8307.pdf

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.

With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PR firm: Havas Paris
Hanna Sebbah
+33 (6) 63 73 30 30.
idemia@havas.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 09:00:00 EEST | Press release

Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521069859/en/ Boomi Named One of The Sunday Times Best Places to Work 2026 Boomi's results speak to a workplace culture that goes well beyond industry norms. The company achieved an average employee happiness score of 86%, rated Excellent, with consistent scores across all six dimensions of WorkL's framework. Most strikingly, Boomi's flight risk, the proportion of employees who may be considering leaving, stood at just 3%, against a technology se

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye